IVVD Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 137080 min ago

@ $4.03

Išleistas: 14 vas. 2024 @ 22:29

Grąža: -40.45%

Ankstesnis signalas: vas. 13 - 21:11

Ankstesnis signalas: Pardavimas

Grąža: 1.26 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	414 423
Vidutinė apimtis	681 782
Rinkos kapitalizacija	286.36M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-0.370 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.280
ATR14	$0.00500 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Green Julie	Buy	240 000	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	110 700	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	97 500	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	160 000	Stock Option (Right to Buy)
2024-01-19	Adimab, Llc	Sell	5 000 000	Common Stock

INSIDER POWER
6.77
Last 36 transactions
Buy: 9 419 589 \| Sell: 5 442 000

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: 0.25 (neutral)

Signal:(49.293) Neutral

Invivyd, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Invivyd, Inc. Koreliacija - Valiuta/Žaliavos

-0.14
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.12
( neutral )

0.00
( neutral )

-0.02
( neutral )

Invivyd, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2023
Pajamos:	$0
Bruto pelnas:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2022
Pajamos:	$0
Bruto pelnas:	$-462 000 (0.00 %)
EPS:	$-2.17

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.32

Financial Reports:

No articles found.

Invivyd, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.